Background
==========

Toxoplasmosis is caused by the zoonotic and ubiquitous *Toxoplasma gondii*, with up to 30% of the world human population affected by this parasite. Infection usually occurs by ingestion of *T. gondii* oocysts from infected cats or consumption of undercooked meat containing the parasite cysts. Environmental, cultural factors and eating habits are thought to be contributing factors in the transmission of this infection \[[@B1]-[@B4]\]. The foetus of an infected mother can acquire this infection by vertical transmission through the placenta during early pregnancy. In congenital toxoplasmosis most of the mothers and newborns are asymptomatic but severe sequelae may develop later in the infant life such as inflammatory lesions, mental retardation, seizures and choriorentitis with or without hydrocephaly. Prompt treatment of the affected child would be possible if diagnosed early \[[@B5]-[@B8]\]. Diagnosis of toxoplasmosis is usually performed by detection of IgG and IgM against *T. gondii*. In addition, IgG avidity test is an important additional test that is routinely performed; with low IgG avidity suggesting acute infection while high IgG avidity confirms chronic infection \[[@B9]\].

*In-vivo* induced antigen technology (IVIAT) is a new and promising method introduced by Martin Handfield *et al.* in 2000 which can be used to determine *in-vivo* induced antigens that are directly related to the human infection and thus reduce false-positive results caused by the differences between proteins expressed during *in-vitro* culture and actual human infection \[[@B10]\]. IVIAT uses sera from patients or animals infected with the pathogen of interest and therefore obviate the need for animal models. Up-regulation of identified genes by IVIAT can be assessed by techniques such as quantitative real time PCR (RT-PCR) or microarray \[[@B10]-[@B12]\]. In a previous study, our group has used IVIAT to identify *in-vivo* induced genes of *T. gondii* which expresses proteins reactive with Toxoplasma specific IgG antibodies in chronically-infected individuals \[[@B13]\].

In the present study we applied IVIAT to identify *in-vivo* induced antigens of *T. gondii* using sera of acutely-infected patients with low anti-Toxoplasma IgG avidity and high IgM positivity. These antigens may be potentially useful as diagnostic markers, vaccine candidates or in increasing our understanding of the disease pathogenesis.

Methods
=======

Parasite strain and growth conditions
-------------------------------------

*In-vitro* culture of *T. gondii* RH strain in Vero cells was performed under conditions previously optimized in our laboratory \[[@B14]\]. Vero cells were washed four times at 85% confluence with phosphate buffered saline (PBS), followed by addition of DMEM medium (Gibco BRL, USA) containing 100 μg/ml streptomycin and 100 IU/ml penicillin (Gibco BRL, USA) with 10% (v/v) fetal bovine serum (Invitrogen, USA). Subsequently the cells were seeded with 1x10^7^*T. gondii* tachyzoites harvested from infected mice. After 3--4 days the maximum release of tachyzoites was observed and the culture containing parasites was centrifuged and the pelleted tachyzoites was kept at −80°C.

To produce *in-vivo* grown tachyzoites, Swiss albino mice were intraperitoneally infected with 1 × 10^3^ tachyzoites of *T. gondii* RH strain. After three to four days post-infection, the peritoneal cavity fluid was aseptically harvested with 5 ml of RPMI-1640 medium containing penicillin streptomycin (RPMI-PS), pH 7.2 (Gibco®, Life Technologies, USA). The supernatant containing tachyzoites was collected, centrifuged, washed with PBS and pelleted tachyzoites immediately kept at −80°C for RNA extraction. Approval from the USM Animal Research Ethics Committee was obtained prior to performing the animal infection.

Serum samples
-------------

Commercial IgM and IgG ELISA kits (Euroimmun, Germany) were used to determine the Toxoplasma serology status of the serum samples in this study. Twelve sera samples were obtained from patients with clinical evidence of toxoplasmosis. Toxoplasma serology performed on the serum samples showed high IgM antibody levels and low IgG avidity indices. These sera were collected by one of the co-authors from Molecular Parasitology Laboratory, Parasitology Department, Pasteur Institute of Iran. Ethical clearance from the institution and informed consents from patients were obtained. Prior to performing IVIAT, equal volume of each serum samples was pooled. Out of a total of 12 serum samples, 10 were individually used to determine sensitivity of selected clones. In addition, another 10 serum samples from healthy individuals which were negative for both anti-Toxoplasma IgM and IgG antibody were individually used to determine specificity of selected clones.

Sera pre-adsorption
-------------------

Sera adsorption was performed according to previously reported protocol with some slight modifications in order to increase efficiency of the process so as to 'completely' remove *in-vitro* antigens \[[@B13],[@B15]\]. One modification was to increase the incubation of pooled sera with each of cell pellet, heat denatured and non-heat-denatured cell lysates of *T. gondii* &*E. coli* XL1-Blue MRF' from 1 h to overnight at 4°C on a shaker. Each step was repeated twice and thimerosol (1%) was added in order to prevent contamination. Serum samples used for sensitivity and specificity determination (section 2.8) were preadsorbed with pellet, heat denatured and non-heat-denatured cell lysates of only *E. coli* XL1-Blue MRF'. The efficiency of sera adsorption at each step was checked using indirect enzyme-linked immunosorbent assay (ELISA) according to the previously optimized protocol \[[@B13]\]. The final adsorbed sera sample was centrifuged and kept at −80°C.

T. gondii expression library
----------------------------

Custom-made *T. gondii* cDNA expression library was constructed in Lambda ZAP® II system (Strategene, USA) using mRNA from *in-vitro* grown *T. gondii* pellet. The previously optimized dilution of cDNA library immunoscreening was 10^3^ for primary screening which produces around 500--1000 plaques per plate. For secondary and tertiary screening 10^4^ and 10^5^ dilutions of cDNA library were used respectively.

cDNA library immunoscreening
----------------------------

For *T. gondii* cDNA library screening a modified version of a previously reported method was used \[[@B16]\]. For primary screening, the 10^3^ dilution of cDNA library was mixed with 600 μl of *E. coli* XL1-Blue MRF' cells at OD~600nm~ 0.5, then plated on LB agar plates 3--4 h in a 42°C incubator until the plaques became visible. On the next day, the agar plates were overlaid with nitrocellulose filter disc pre-saturated with 10 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and incubated overnight at 28°C. The filters were then removed from the plates, washed (colony side up) with PBS-Tween 20, blocked with 1:5 dilution of Super Block solution (Thermo Scientific, USA) and incubated overnight with adsorbed pooled serum at dilution 1:100. Subsequently after three step of washing with PBS-Tween 20 the filters were incubated with peroxidase-anti-human IgG (Invitrogen, USA) at 1:3000 dilution or peroxidase-anti-human IgM (Invitrogen, USA) at 1:2000 dilution for 1 h, washed and then developed using chemiluminescence substrate (Roche Diagnostics, Germany). The phage plaques on the agar plates which corresponded to positive plaque images on the X-ray film were cored out and subjected to secondary and tertiary screenings using the same serum. For secondary and tertiary screenings, higher dilutions were used to produce much lower density plaques (\<50 per plate) with many isolated clones. Final positive clones were isolated and placed in 500 μl SM buffer containing 3% chloroform overnight at 4°C. Part of them were used directly for *in-vivo* excision, while the rest were centrifuged and the supernatant placed in 500 μl SM buffer with 7% DMSO for long-term storage at −80°C.

*In-vivo* excision and plasmid purification
-------------------------------------------

*In-vivo* excision was performed to convert the recombinant phages to recombinant plasmids. The selected phage clone (in 250 μl SM buffer) and 1 μl ExAssist helper phage (\>106 pfu/ml) (Stratagene, USA) was added to 200 μl of *E. coli* XL1-Blue MRF' cells at OD~450nm~ 1.0. The culture was incubated at 37°C for 15 min followed by addition of 3 ml of LB broth and incubation in 65°C for 20 min. After centrifugation 10 μl of supernatant (excised phagemids) was mixed with 200 μl of SOLR cells (Stratagene, USA) at OD 1.0 (405 nm) and plated overnight at 37°C on LB ampicillin agar plate. Plasmids from each sample was purified using commercial plasmid preparation kit (Promega, USA) and sent for sequencing using M13 forward and reverse primers. The sequences identified by IVIAT in current study after sequencing were then analyzed using GenBank and ToxoDB (<http://toxodb.org/toxo>) databases. ToxoDB, a functional genomic database for *T. gondii* which incorporates sequence and annotation data, is integrated with other genomic-scale data, including community annotation; expressed sequence tags (ESTs) and gene expression data \[[@B17]\].

Quantitative real-time PCR analysis
-----------------------------------

The forward and reverse primers for each of the sequences were designed using Primer Express 2.0 software (Applied Biosystems, USA). Table [1](#T1){ref-type="table"} shows the primers designed based on sequences of IgM-detected genes; while Table [2](#T2){ref-type="table"} shows the primers designed based on sequences of IgG-detected genes. Pooled *in-vitro*-grown tachyzoites from 20 culture flasks (75 cm^2^) (Nunclon, Roskilde, Denmark) and pooled *in-vivo*-grown tachyzoites from 35 mice were prepared as described above. Total RNA was extracted and purified using RNAeasy mini kit (Qiagen, Germany). The DNase-treated RNA samples were converted to cDNA using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, USA). Real-time PCR was performed using Quanti FastTect SYBR Green PCR Kit (Qiagen, Germany) in a Rotor Gene 6000 Multiplex System (Corbett Research, Australia). Each of the reaction mix comprised 5 μl of cDNA (200 to 400 ng), 200 pmol of each primer (forward and reverse) and 12.5 μl of 2× SYBR Green mix and sufficient amount of dH~2~O to bring the volume to 25 μl. The parameters for thermocycler were as follow: 95°C for 5 min short hot-start, followed by 40 cycles of 95°C for 10 sec for denaturing and subsequently combine annealing/extension at 60°C for 30 sec. At the final step of real-time PCR, melting curves with 1°C temperature increments from 72°C to 95°C were incorporated. Data analysis was performed using Rotor Gene 6000 Series Software 1.7. First the expression level was normalized to the reference β-actin gene as housekeeping gene. Next the fold change of *in-vivo* expression of the gene relative to its *in-vitro* expression level was calculated using 2^-^ΔΔ^Ct^ method \[[@B18]\].

###### 

**Primers used in real-time PCR analysis of*T.gondii*IVIAT identified genes by IgM**

  **GenBank ID/accession no.**   **Primer**                         
  ------------------------------ ---------------------------------- --------------------------------
  ^***\*\****^**β*-Actin***      \*F                                5′-TCACACTGTGCCCATCTACGA-3′
  \*R                            5′-GTGGTGAAGCCGTATCCTCTCT-3′       
  **7895406**                    F                                  5′-ACCGACTCGAAGCACAACAGT-3′
  R                              5′-CATCGTAGGTGACGAACAATGC-3′       
  **7898829**                    F                                  5′- CAATGTTTCGGGCAGCTCAT -3′
  R                              5′- GCTGTACTGAAACCGTCGATGTAG -3′   
  **7894091**                    F                                  5′- CCACTCAAGCAGTTCCTGAAGA -3′
  R                              5′- GATCTCCGCGAAATCTGTCTCT -3′     
  **7900912**                    F                                  5′- CGCATTTACAAGCGCCTGAT -3′
  R                              5′- TTCCACGCCTCGTTTACATG -3′       
  **7899945**                    F                                  5′- CTTCTCGACGACATGCATCTG -3′
  R                              5′- TGGACGCACTGGATGTTCTG -3′       
  **7893976**                    F                                  5′- AGCGCAGCAAGAACCAAGA -3′
  R                              5′- TTCCTCAAGAAGGCCATGGA -3′       
  **7893824**                    F                                  5′- CTCACGTACGAGGCTAGATCCA -3′
  R                              5′- GTCCGCCAGGGCATTCTATT -3′       
  **7899621**                    F                                  5′- AGGCACAGGCTCCACCATAC -3′
  R                              5′- AGCTCCAGGACGCGTAAGAG -3′       
  **7901413**                    F                                  5′- TCTGAAGCTGCAAGGTTCCA -3′
  R                              5′- TTGCAGAGTAGGCTCGTCAAAC -3′     
  **7894150**                    F                                  5′- TCCTCGAACGGCAGAGAAA -3′
  R                              5′- CCCCTCAGGTGTGAAGACATCT -3′     
  **7895338**                    F                                  5′- AGAGCCGGTAGCACTGTGTTC -3′
  R                              5′- CGGTAACCCGGTGGACTTCT -3′       
  **7898197**                    F                                  5′- GGATTTCGGCACGCTCAAT -3′
  R                              5′- CAACTGTGGCTCCCGACTACTT -3′     
  **7895974**                    F                                  5′-CCAAATCGGTTCGCTCATGT-3′
  R                              5′-GCAAAGGCCGGAGAATTCAT-3′         
  **7900011**                    F                                  5′-CACGCTAACTGTTTCAGGTACGA-3′
  R                              5′-TACAGCAGCGTGTTCATTTGC-3′        
  **7895000**                    F                                  5′-TCCAACATCCCGACCTGATC-3′
  R                              5′-GCTTCGACCTTCGCATTCTTC-3′        
  **L06091.1**                   F                                  5′-CAGACTCCTTGCTCTCTTCTTGAA-3′
  R                              5′-GTTGTGTCACTACTGCGATTGTTG-3′     
  **7896316**                    F                                  5′-AAGGTGCTTCATCCGCCATA-3′
  R                              5′-GGTCTTGCATATCTCGCCATTC-3′       
  **7894239**                    F                                  5′-GAACTGTTTCAATGCGTCGATT-3′
  R                              5′-GTGATCCAATCGCACACTCTTTT-3′      
  **7896580**                    F                                  5′-CCTTCTGGTTAGCCACATCTGAT-3′
  R                              5′-GGCGACGAAGATGATTTTGAC-3′        
  **7899034**                    F                                  5′-CCTGGAACGTCCTTTCTGGAT -3′
  R                              5′-ATCTAACCGTCGCGCTGGTA -3′        
  **7899034**                    F                                  5′-ATGTTCCCGATCCAGAGCAA-3′
  R                              5′-GGTGTGGCTGTCTCCCTATTTT-3′       
  **AY707938.1**                 F                                  5′-GAACGCGAACAATGAGTTTG-3′
  R                              5′-CCGCTGGTCGAAATAATGATG-3′        
  **7894324**                    F                                  5′-GTTAATCAGGAGCAGACCCGATA-3′
  R                              5′-TAAGCTACCCCTGAGCAAGTTGT-3′      
  **AF364813.1**                 F                                  5′-GGTGGAAAGTGAATACCGTGGAT-3′
  R                              5′-CAGTGAGTCCGAATGCCAAAT-3′        
  **7900910**                    F                                  5′-GCCTGCAACATGTCCAACTTC-3′
  R                              5′-TCAGCGGCTAAGCGAAAAAG-3′         
  **7896316**                    F                                  5′-CATACGGATAGGCGGTCATGTA-3′
  R                              5′-GTATACGAACGCCCTGATGTTG-3′       
  **7897539**                    F                                  5′-ATGCAAGACCCAAGGCAAAC-3′
  R                              5′-TGTACGGAACGCTTCTTCGA-3′         
  **7895127**                    F                                  5′-GCGAAAGTCAAACGGAATGG-3′
  R                              5′-TTCTGCGCGGAGTCGTTATT-3′         
  **7896796**                    F                                  5′-GCTTTTACCTGCTCGGGAAGT-3′
                                 R                                  5′-AACGCATCTCACACGGATAGC-3′

*\*F* forward, *R* reverse.

*\*\**β*-Actin* was used as the housekeeping gene.

###### 

**Primers used in real-time PCR analysis of*T.gondii*IVIAT identified genes by IgG**

  **GenBank ID/accession no.**   **Primer**                       
  ------------------------------ -------------------------------- --------------------------------
  ^***\*\****^**β*-Actin***      \*F                              5′-TCACACTGTGCCCATCTACGA-3′
  \*R                            5′-GTGGTGAAGCCGTATCCTCTCT-3′     
  **7901108**                    F                                5′-AAAGATGCTCCACGCCAACT-3′
  R                              5′-GTTTGTCCACGTTGCTTCCA-3′       
  **7901478**                    F                                5′-TGAGCCAGAAACCTGACAAACA-3′
  R                              5′-ATCGCCTTTTCCGCTGATTT-3′       
  **7894322**                    F                                5′-TCCTAAAGCTCGGCGGAATT-3′
  R                              5′-CGGTTTGGGCTTTCCAGTTT-3′       
  **7894761**                    F                                5′-AGGCGTTTCAACCGACTCTGT-3′
  R                              5′-ACCTGTGGCACAACAAGACATC-3′     
  **7897485**                    F                                5′-CAAGCGTGAGTTCGAGCAATAC-3′
  R                              5′-GGCTTCCCATTTCGGTCATA-3′       
  **7899395**                    F                                5′-TCGTGGTGGACAAGGTATAGGAT-3′
  R                              5′- CCATAGTTGTCGGAAGAGTCGTT-3′   
  **7895435**                    F                                5′- GGGAAAGCATCTGGCTTCAA-3′
  R                              5′- GAGGAACGGAAAGTAGCGGAAT-3′    
  **7895096**                    F                                5′-CTCGAAACGATCGCTGCTTT-3′
  R                              5′-ACTCCCGCAGAGTTCAAGACTT-3′     
  **7895077**                    F                                5′-CCTTCCACAAGTTGGCACAGA-3′
  R                              5′-CAGTAGCTCCTCAAGCAGTGACA-3′    
  **7897605**                    F                                5′-GATGATCGAAGCTCGCAAGTG-3′
  R                              5′-TAGACAAGGTGCCGCATCAAC-3′      
  **7899217**                    F                                5′-GTTCCTCGAGCTTTCCAACCT-3′
  R                              5′-AGAGCTGCATCTGGAGCAGAA-3′      
  **AM055942.3**                 F                                5′-GAGGCACCGCTTCTTCTATACTG-3′
  R                              5′-TGGGATCGTGTAAGCCATAGC-3′      
  **7894058**                    F                                5′-TTTCCCTGCGGAGCAGTCT-3′
  R                              5′-CGCCTGCAACCTGAGATGA-3′        
  **7893896**                    F                                5′-GCGAAAGGTCTGGAACATTTG-3′
  R                              5′-GGCAGGTAGGAAAGGAAATCGT-3′     
  **7899266**                    F                                5′-GGCACTTGTCAATGCAGAACA-3′
  R                              5′-CTAATTGACCGGTGCACGAAA-3′      
  **7893521**                    F                                5′-GGAGGTCATCCTGTGGACTCA-3′
  R                              5′-GGCTCACGACTTTCACCTTCA-3′      
  **7893531**                    F                                5′-CGATACATGCGGCAGAGTCA-3′
  R                              5′-TGCTGGCTCGTCACATTCAG-3′       
  **7896164**                    F                                5′-ATCTCGGGAGTCTTCAGCAGACT-3′
  R                              5′-GACGGCTGTTTCTCGACTTTTC-3′     
  **7896097**                    F                                5′-TGTTGCTACCATGGGCCATT-3′
  R                              5′-TGTATCTGTGCCGGTCTTCGT-3′      
  **7901507**                    F                                5′-CGTATTCAAGCGCTGTTCGA -3′
  R                              5′-GAGACGATTGGCAGCGAATT -3′      
  **7894761**                    F                                5′-AACCGACTCTGTCGCATCTGT-3′
  R                              5′-CAAACCTGTGGCACAACAAGA-3′      
  **7900407**                    F                                5′-GCCTTCCTCGTAACCCAACTT-3′
  R                              5′-AAGCTTGCCAGAACGACGAA-3′       
  **7897848**                    F                                5′-CTGATTCGGGCACTGATTGA-3′
  R                              5′-GACGCGAAAAAGAGGGCATA-3′       
  **7900113**                    F                                5′-CGAGTTCTTTCGCGCTTTCT-3′
  R                              5′-ATGGTTGGCAGACGGTCAAG-3′       
  **7899268**                    F                                5′-TCAGCTCGGAAGCACAGAATC-3′
  R                              5′-ACGTGTCAGGCGGTGAATACT-3′      
  **7893794**                    F                                5′-TCCCGAAGGGAAAAAGTAGTCATA-3′
  R                              5′-TTTGTCTTGGACTTCCGTATACCA-3′   
  **7893464**                    F                                5′-CGAACCCTGCCAATTCTCAT-3′
  R                              5′-TCCATCCCCTCAGCAAAGTT-3′       
  **7899477**                    F                                5′-CTGTGTAAGGCGAATTTCTTTCG-3′
  R                              5′-AGAAGAGAATCTGGCACGATGTG-3′    
  **AY424892.1**                 F                                5′-CAGGAAGCCATGCACACTGT-3′
                                 R                                5′-GGCGACTCGATCCATTCCTA-3′

^*\**^*F* forward, *R* reverse.

^*\*\**^β*-Actin* was used as the housekeeping gene.

Sensitivity and specificity determination
-----------------------------------------

To determine the sensitivity and specificity of selected clones, one clone was plated per petri dish and immunoscreening was performed as above with the exception that individual serum samples from acutely infected patients were used instead of pooled sera. Each nitrocellulose membrane was divided into six sections i.e. for six different serum samples. Positive and negative controls were included in each experiment. Sensitivity refers to the number of serum samples from acute-infected individuals (n = 10) which were reactive with the protein expressed by a particular clone. Thus if 8 serum samples are reactive out of 10, the sensitivity of the clone in the detection of *anti-Toxoplasma* antibodies in that group of serum samples is 8/10 or 80%. Specificity refers to the number of serum samples from healthy individuals (n = 10) which were not reactive with the protein expressed by a particular clone. Thus if 9 serum samples are not reactive out of the 10, the specificity of the clone in the detection of *anti-Toxoplasma* antibodies is 9/10 or 90%.

Results
=======

Adsorption of pooled sera from patients with acute toxoplasmosis
----------------------------------------------------------------

Figures [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B show that the pooled sera were exhaustively pre-adsorbed against *T. gondii* and *E. coli* XL1-Blue MRF' in-vitro antigens. Most of the reductions in OD values were observed after pre-adsorption with the pellet of the organisms. After the last step of serum pre-adsorption, the OD values of 0.001-0.009 were observed for serum diluted 1:100, which was the dilution used in the immunoscreening step.

![**Optical densities (OD) of pooled serum adsorped by*E. coli*and*T. gondii*. (A)** serum adsorped by three different forms of *E. coli* XL1-Blue MRF', and **(B)** serum adsorped by three different forms of *T. gondii*. **1**-pooled non-preabsorped serum (control); **2**-serum adsorped by whole cell; **3**-serum adsorped by non-heat denatured cell lysate; and **4**-serum adsorped by heat denatured cell lysate.](1471-2334-13-287-1){#F1}

cDNA library tittering, screening and clone isolation
-----------------------------------------------------

Approximately 10 000 and 14 000 clones from *T.gondii* recombinant phage cDNA library were screened with HRP-conjugated anti-human IgM and IgG respectively. A total of 35 clones were randomly selected from about 200 positive clones after the three stage immunoscreenings (primary, secondary and tertiary) with anti-human IgM-HRP. After sequencing, 29 clones showed high homology (80-100 %) to *T. gondii* genes (Table [3](#T3){ref-type="table"}). Meanwhile a total of 38 clones were randomly selected from about 300 positive clones after the three stage immunoscreenings with anti-human IgG-HRP. After sequencing, 29 clones showed high homology (80-100%) to *T. gondii* genes (Table [4](#T4){ref-type="table"}).

###### 

***Toxoplasma gondii*IVIAT- identified genes by immunoscreening of cDNA library using anti-human IgM-HRP**

  **GenBank ID/accession no.**                                                  **Gene ID in Toxo DB**   **Gene name**   **Description**                                  **Homology percentage**                                                                                  
  ----------------------------------------------------------------------------- ------------------------ --------------- ------------------------------------------------ -------------------------------------------------------------------------------------------------------- ------
  **1**                                                                         7895406                  TGME49_026460   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             99%
  **2**                                                                         7898829                  TGME49_057020   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             86%
  **3**                                                                         7894091                  TGME49_030160   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             97%
  **4**                                                                         7900912                  TGME49_066920   phosphodiesterase                                *Toxoplasma gondii ME49* phosphodiesterase, putative, mRNA                                               97%
  **5**                                                                         7899945                  TGME49_023050   40s ribosomal protein S20                        *Toxoplasma gondii ME49* 40s ribosomal protein S20, putative                                             99%
  **6**                                                                         7893976                  TGME49_046620   G10 protein                                      *Toxoplasma gondiiME49* G10 protein, putative                                                            99%
  **7**                                                                         7893824                  TGME49_066140   sterol-regulatory element binding protein site   *Toxoplasma gondii ME49* sterol-regulatory element binding protein site 2 protease, putative, mRNA       83%
  **8**                                                                         7899621                  TGME49_060190   microneme protein                                *Toxoplasma gondiiME49*                                                                                  95%
  Toxoplasma gondii strain RH microneme protein 13 (MIC13) gene, complete cds                                                                                                                                                                                                      
  **9**                                                                         7901413                  TGME49_004530   microneme protein                                *Toxoplasma gondii ME49* microneme protein TgMIC11 precursor (MIC11) mRNA, complete cds                  80%
  **10**                                                                        7894150                  TGME49_001880   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             81%
  **11**                                                                        7895338                  TGME49_071740   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             80%
  **12**                                                                        7898197                  TGME49_086550   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             81%
  **13**                                                                        7895974                  TGME49_048600   aspartate aminotransferase                       *Toxoplasma gondii ME49* aspartate aminotransferase, putative, mRNA                                      91%
  **14**                                                                        7900011                  TGME49_093510   poly(ADP)-ribose polymerase domain-containing    *Toxoplasma gondiiME49* poly(ADP)-ribose polymerase domain-containing                                    99%
  **15**                                                                        L06091.1                 TOXGRA5A        dense granule precursor (GRA5) gene              *Toxoplasma gondii strain RH* clone pcGRA5-IR dense granule antigen                                      100%
  **16**                                                                        AM055943.1 7896316       TGME49_008440   cytoplasmic protein Cyt16                        *Toxoplasma gondii RH* genomic DNA chromosome Ib, cytoplasmic protein Cyt16 (cyt16) gene, complete cds   93%
  **17**                                                                        7894239                  TGME49_054870   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             89%
  **18**                                                                        7896580                  TGME49_008830   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             91%
  **19**                                                                        7899034                  TGME49_057360   Hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             99%
  **20**                                                                        7899034                  TGME49_057360   hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             99%
  **21**                                                                        AY707938.1               TGME49_071050   SRS34A (= SAG2A, P22)                            *Toxoplasma gondii ME49* surface antigen P22 3′ flanking sequence                                        100%
  **22**                                                                        7894324                  TGME49_030180   hypothetical protein                             *Toxoplasma gondii ME49* hypothetical protein                                                            98%
  **23**                                                                        AF364813.1               TGME49_014940   MIC2-associated protein M2AP                     *Toxoplasma gondii ME49* MIC2-associated protein precursor, gene, complete cds                           99%
  **24**                                                                        7900910                  TGME49_066900   cyclin, N-terminal domain-containing protein     *Toxoplasma gondiiME49* cyclin, N-terminal domain-containing protein, mRNA                               100%
  **25**                                                                        7895521                  TGME49_058470   Hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             99%
  **26**                                                                        AM055943.1 7896316       TGME49_008440   hypothetical protein                             *Toxoplasma gondii RH* genomic DNA chromosome Ib                                                         98%
  **27**                                                                        7897539                  TGME49_116540   Hypothetical protein                             *Toxoplasma gondiiME49* hypothetical protein                                                             97%
  **28**                                                                        7895127                  TGME49_027280   dense granule protein 3                          *Toxoplasma gondii ME49* dense granule protein 3, mRNA                                                   90%
  **29**                                                                        AM055943.1 7896796       TGME49_121620   dynamic-like protein                             *Toxoplasma gondii RH* genomic DNA chromosome Ib                                                         96%

###### 

***Toxoplasma gondii*IVIAT- identified genes by immunoscreening of cDNA library using anti-human IgG-HRP**

  **GenBank ID/accession no.**   **Gene ID in Toxo DB**   **Gene name**   **Description**                      **Homology percentage**                                                                                                
  ------------------------------ ------------------------ --------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------- -----
  **1**                          7901108                  TGME49_069250   26S proteasome regulatory subunit    *Toxoplasma gondii ME49* 26S proteasome regulatory subunit, putative                                                   95%
  **2**                          7901478                  TGME49_097940   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           99%
  **3**                          7894322                  TGME49_030160   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           93%
  **4**                          7894761                  TGME49_061750   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           98%
  **5**                          7897485                  TGME49_005180   U1 small nuclear ribonucleoprotein   *Toxoplasma gondii ME49* U1 small nuclear ribonucleoprotein, putative                                                  95%
  **6**                          7899395                  TGME49_037230   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           80%
  **7**                          7895435                  TGME49_024460   aminopeptidase N                     *Toxoplasma gondii ME49* aminopeptidase N, putative                                                                    82%
  **8**                          7895096                  TGME49_027910   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           95%
  **9**                          7895077                  TGME49_025560   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           99%
  **10**                         7897605                  TGME49_025080   40S ribosomal protein S18            *Toxoplasma gondii ME49* 40S ribosomal protein S18, putative                                                           84%
  **11**                         7899217                  TGME49_068830   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           94%
  **12**                         AM055942.3               TGME49_095420   hypothetical protein                 *Toxoplasma gondii RH* genomic DNA chromosome Ia                                                                       87%
  **13**                         7894058                  TGME49_002840   zinc finger (C3HC4 type)             *Toxoplasma gondii ME49* zinc finger (C3HC4 type)/FHA domain-containing protein                                        97%
  **14**                         7893896                  TGME49_075310   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           94%
  **15**                         7899266                  TGME49_047530   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           96%
  **16**                         7893521                  TGME49_018520   protein MIC6                         *Toxoplasma gondii* micronemal protein MIC6 (MIC6) mRNA, complete                                                      95%
  **17**                         7893531                  TGME49_018720   protein kinase                       *Toxoplasma gondii ME49* calcium-dependent protein kinase, putative                                                    91%
  **18**                         7896164                  TGME49_025060   nucleoredoxin                        *Toxoplasma gondii ME49* nucleoredoxin, putativ                                                                        98%
  **19**                         7896097                  TGME49_026520   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           98%
  **20**                         7901507                  TGME49_078510   Protein phosphatase 2C               *Toxoplasma gondii ME49* protein phosphatase 2C, putative                                                              95%
  **21**                         7894761                  TGME49_061750   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           98%
  **22**                         7900407                  TGME49_078450   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           95%
  **23**                         7897848                  TGME49_095620   zinc finger (CCCH type)              *Toxoplasma gondii ME49* zinc finger (CCCH type) protein, putative                                                     91%
  **24**                         7900113                  TGME49_035990   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           91%
  **25**                         7899268                  TGME49_045880   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           88%
  **26**                         7893794                  TGME49_067740   hypothetical protein                 *Toxoplasma gondiiME49* hypothetical protein                                                                           99%
  **27**                         7893464                  TGME49_071050   surface antigen P22                  *Toxoplasma gondii strain 14* surface antigen P22 3′ flanking sequence                                                 85%
  **28**                         7899477                  TGME49_049670   cysteine proteinase                  *Toxoplasma gondii ME49* cysteine proteinase (cp1) mRNA, complete cds                                                  95%
  **29**                         AY424892.1               AY424892.1      UDP-N-acetyl-D-galactosamine         *Toxoplasma gondii* UDP-N-acetyl-D galactosamine:polypeptide N-acetylgalactosaminyltransferase T3 gene, complete cds   90%

Assessment of IVIAT-identified gene expression by real-time PCR
---------------------------------------------------------------

Due to the large number of samples in this study and the use of different control samples for each round of experiments, the detailed data could not be placed in one table. Therefore only the fold changes of the examined sequences are presented in Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"} to show the relative expression levels between *in-vivo* and *in-vitro* grown parasites for IgM-detected sequences and IgG-detected sequences respectively. Of the 29 IgM-detected genes analyzed, 20 (69%) were up-regulated *in-vivo* relative to their *in-vitro* expression levels with fold changes between 3.11 and 330.8 (Figure [2](#F2){ref-type="fig"}A). Table [5](#T5){ref-type="table"} shows the fold changes of the expression of the genes; the results indicated that there were significant increases, ranging from 3.11 to 330.8-folds of the gene expression levels of *in-vivo* over *in-vitro* grown parasites for 20 of 28 IgM-detected genes. Of the 29 IgG-detected genes analyzed, 10 (34%) were up-regulated *in-vivo* relative to their expression levels *in-vitro* with fold changes between 1.59 and 499.86 (Figure [2](#F2){ref-type="fig"}B). Table [6](#T6){ref-type="table"} shows the fold changes of the expression of the genes; the results indicated that there were significant increases, ranging from 1.31 to 449.86-folds of the expression levels of *in-vivo* over *in-vitro* for 11 of 29 IgG-detected genes.

###### 

**Relative mRNA expression levels of*T.gondii*IVIAT-identified genes detected by IgM using 2**^**-**^ΔΔ^**Ct**^**method**

  **No**   **GenBank ID**   **Fold change**   **Protein encoded by gene**
  -------- ---------------- ----------------- ------------------------------------------------
  **1**    7895406          0.86               
  **2**    7898829          330.8             hypothetical protein
  **3**    7894091          0.97               
  **4**    7900912          0.14               
  **5**    7899945          0.00048            
  **6**    7893976          0.6                
  **7**    7893824          53.81             sterol-regulatory element binding protein site
  **8**    7899621          8.6                
  **9**    7901413          35.75             microneme
  **10**   7894150          25.28             hypothetical protein
  **11**   7895338          179.76            hypothetical protein
  **12**   7898197          43.11             hypothetical protein
  **13**   7895974          8.87               
  **14**   7900011          0.62               
  **15**   L06091.1         3.6                
  **16**   7896316          0.3                
  **17**   7894239          3.22               
  **18**   7896580          4.89               
  **19**   7899034          0.09               
  **20**   7899034          0.26               
  **21**   AY707938.1       27.28             SRS34A
  **22**   7894324          32.89             hypothetical protein
  **23**   AF364813.1       22.6              MIC2-associated protein M2AP
  **24**   7900910          6.82               
  **25**   7895521          3.78               
  **26**   7896316          0.24               
  **27**   7897539          6.49               
  **28**   7895127          3.11               
  **29**   7896796          8.5                

###### 

**Relative mRNA expression levels of*T.gondii*IVIAT-identified genes detected by IgG using 2**^**-**^ΔΔ^**Ct**^**method**

  **No**   **GenBank ID**   **Fold change**   **protein encoded by gene which are upregulated \>10 ×**
  -------- ---------------- ----------------- ----------------------------------------------------------
  **1**    7901108          1.67               
  **2**    7901478          0.80               
  **3**    7894322          1.31               
  **4**    7894761          0.33               
  **5**    7897485          0.36               
  **6**    7899395          0.05               
  **7**    7895435          0.01               
  **8**    7895096          0.16               
  **9**    7895077          0.98               
  **10**   7897605          0.18               
  **11**   7899217          3.03               
  **12**   AM055942.3       60.97             hypothetical protein
  **13**   7894058          0.01               
  **14**   7893896          0.05               
  **15**   7899266          499.86            hypothetical protein
  **16**   7893521          1                  
  **17**   7893531          2.84               
  **18**   7896164          30.70             nucleoredoxin
  **19**   7896097          2.15               
  **20**   7901507          14.86             Protein phosphatase 2C
  **21**   7894761          0.18               
  **22**   7900407          1.59               
  **23**   7897848          1.75               
  **24**   7900113          0.1                
  **25**   7899268          0.08               
  **26**   7893794          0.23               
  **27**   7893464          0.01               
  **28**   7899477          0.02               
  **29**   AY424892.1       0.02               

![**Relative gene expression level (*in-vivo*to*in-vitro*) for*T.gondii*genes identified by IVIAT. (A).** Genes detected by IgM antibody **(B).** Genes detected by IgG antibody. The y axis presented the identified genes by number.](1471-2334-13-287-2){#F2}

Sensitivity and specificity evaluation
--------------------------------------

The top three most up-regulated IgM- and IgG-detected clones were subjected to sensitivity and specificity analysis. Figure [3](#F3){ref-type="fig"} shows an example of the immunoblot results, and Table [7](#T7){ref-type="table"} shows the summary of the results. High sensitivity (90.0%) was observed for three IgM-detected clones and one of the IgG-detected clones. However the specificity was generally not high, the best was a moderate specificity of 70% from a hypothetical protein expressed by an IgM-detected clone (GenBank accession no. 7898829).

![**Representative results of sensitivity evaluation of clone which expressed sterol-regulatory element binding protein site.** AS1-AS4: serum from persons with acute toxoplasmosis. HC: serum from healthy person.](1471-2334-13-287-3){#F3}

###### 

Sensitivity and specificity results for three up-regulated IgM and IgG-detected clones identified by IVIAT

  **GenBank ID**   **Fold change**   **Sensitivity**   **Specificity**   **Antibody detection**
  ---------------- ----------------- ----------------- ----------------- ------------------------
  **7898829**      330.8             90% (9/10)        70% (7/10)        IgM
  **7893824**      53.81             90% (9/10)        50% (5/10)        IgM
  **7895338**      179.76            90% (9/10)        40% (4/10)        IgM
  **AM055942.3**   60.97             60% (6/10)        60% (6/10)        IgG
  **7899266**      499.86            60% (6/10)        70% (7/10)        IgG
  **7896164**      30.70             90% (9/10)        60% (6/10)        IgG

Discussion
==========

IVIAT has been applied in the study of several pathogenic microorganisms based on the assumption that conventional genetic and biochemical *in-vitro* approaches cannot mimic the real complex and dynamic *in-vivo* situation of human infection \[[@B19]-[@B28]\]. In our recent published report, *T.gondii* genes preferentially expressed *in-vivo* were identified via immunoscreening of *T.gondii* expression library with sera from chronically-infected individuals followed by real time PCR to confirm the up-regulation of the identified genes. There were increased expression levels of RNA of three genes i.e. SRS3 and two hypothetical protein genes from *in-vivo* grown *T.gondii* relative to the same genes from *in-vitro* grown parasite \[[@B13]\]. This approach does not reflect all of the antigens that are produced *in-vivo* by the eukaryotic parasite, considering that a prokaryotic expression system was used in constructing the cDNA library. Nevertheless, this approach would be expected to identify some of the *in-vivo* induced antigens of the parasite \[[@B13]\].

The rationale for use of *in-vitro* instead of *in-vivo* grown *T. gondii* has been explained in our previous report \[[@B13]\]. A large quantity of 'clean tachyzoites' was needed to make a good high titre *T. gondii* cDNA library. As compared to the use of mice as host, the *in-vitro* method had less contamination and produced higher quantity of parasites in a shorter period of time. Although all the RNA may not be exactly the same between *in-vivo* and *in vitro* grown parasites, there should be substantial similarities between them to enable us to observe difference in expression levels between them. Moreover IVIAT was introduced in order to reduce the need to use animals. There are also many other IVIAT studies which used *in-vitro* grown organisms \[[@B16],[@B20],[@B29],[@B30]\]. For the same reasons (i.e. better purity and yield), we used *T. gondii* RH strain instead of ME49 strain, although the available genome information was derived from the latter.

The main serological marker for the diagnosis of acute toxoplasmosis is specific IgM antibody, along with IgG antibody of low avidity \[[@B31]\]. In the present study 29 *T. gondii* sequences were detected by each IgM and IgG secondary antibodies using sera from individuals with serological evidence of acute infection. Due to resource constraints, we did not endeavour to identify all of the IVIAT-detected clones using a high-throughput methodology. However the random selection of the clones for expression analysis by real-time PCR hopefully will provide a 'snapshot' of the *in-vivo* induced antigens of *T. gondii.* The results of the transcriptional profiling suggested the induction of genes that have been described as involved in parasite invasion and motility, cellular metabolism, as well as other unknown functions. It is notable that the percentage of up-regulated genes among the IgM-identified clones were twice the percentage of up-regulated genes among the IgG-identified clones. It is also interesting to note that among the IgM and IgG-detected proteins, most were hypothetical proteins namely 14 of 29 and 16 of 29 respectively. Limited sensitivity and specificity evaluation of the top three most up-regulated IgM- and IgG-detected clones showed that none had good specificity, thus further testing with more serum samples were not performed.

Three different microneme proteins namely MIC6, MIC11, MIC13 and a MIC2 associated protein were identified in this study. MIC6 showed no difference in the mRNA expression levels *in-vivo* over *in-vitro,* but the other three genes detected by IgM (MIC11, MIC13 and MIC2 associated protein) showed significant increases of mRNA expression level of *in-vivo* grown *T.gondii* in comparison to *in-vitro* grown *T. gondii*. Micronemes are sub-cellular organelles that belong to apicomplexan protozoans which secrete proteins (MICs) known to be responsible for the gliding motility and subsequent invasion process of *T. gondii*\[[@B32]\]. MIC11 is a conserved microneme protein in apicomplexan protozoans that is secreted in a calcium dependent manner while MIC13 has been reported as a successful vaccine candidate against chronic infection and congenital toxoplasmosis in mice \[[@B33],[@B34]\]. In this study, the increased expression levels of MIC11, MIC13 and a MIC2 associated protein mRNA observed in the *in-vivo* grown tachyzoites may be due to their role in attachment and invasion of the tachyzoites in the host during acute infection.

Meanwhile, sequences of DNA chromosome Ιb were detected by IgM whereby three sequences which code a dynamic-like protein, a hypothetical protein and cyclin-N terminal domain showed increased level of mRNA expression of *in-vivo* grown over *in-vitro* grown *T. gondii*. Besides, a high increase in the mRNA expression levels (60.67 fold change) was observed for DNA chromosome Ιa sequence that was detected by IgG. Comparative studies between the chromosome genomes of *T. gondii* RH Type I and ME49 Type II strains revealed polymorphisms at a frequency of \~1 in 100 bp among all chromosomes except chromosome Ia (chrIa). Chromosome Ia has the same gene content and structural elements in both strains and this suggest that chrIa has monomorphic inheritance compared to the rest of the *T. gondii* chromosomes for all three clonal lineages although the biological basis remains unknown. The unusual monomorphism of chrIa has led us to the conclusion that genes located on this chromosome may allow some fitness advantage \[[@B35]\].

Eleven other genes with more than 10 times fold changes include nucleoredoxin, protein phosphatase 2C, sterol regulatory protein, surface antigen P22 3' flanking sequence \[SRS34A (= SAG2A, P22)\] and six ORF coding hypothetical proteins. We were most intrigued by the observation of a very high expression level for one of the up-regulated genes detected by IgG, with *in-vivo* over *in-vitro* fold change of 499.86. Unfortunately the function of the gene is unknown. Nucleoredoxin (NRX) is a novel gene which encodes a protein similar to ATrx1, a member of thioredoxins (TRX) family. Nucleoredoxin is highly conserved in all the kingdoms of living organisms and was formerly reported to be nuclear and more recently cytosolic. It appears to play a role in signal transduction and may be a redox regulator factor of the nuclear proteins \[[@B36],[@B37]\].

Protein phosphatase 2C (PP2C) is a Mn2+ or Mg2 -dependent protein Ser/Thr phosphatase secreted by rhoptry, a secretory organelle of *T. gondii*. It was identified in a proteomic survey of rhoptry proteins (ROPs), and found to be essential for the invasion process of apicomplexan parasites \[[@B38]\]. Host cell invasion and motility in apicomplexa protozoa occurs through actin polymerization as the main process. Actin monomers and their cap filaments in *T. gondii* are secreted by toxofilins and its activities *in-vitro* and *in-vivo* are dependent on phosphorylation of this protein. Recently a type 2C phosphatase has been reported to be involved in toxifilin phosphorylation and activity \[[@B39]\].

Sterol regulatory element-binding proteins (SREBPs) were found to be one of the three most up-regulated sequences detected by IgM in this study. SREBPs are basic-helix-loop-helix leucine zipper class of transcription factors which are specific for fatty acid and cholesterol synthesis. When the level of sterols is low, SREBPs are cleaved to a water soluble N-terminal domain which is then translocated to the nucleus \[[@B40]\].

SRS34A (= SAG2A, P22), is a plasma membrane gene of *T. gondii* found during and after tachyzoite invasion. SAG family of proteins which cover the surface of *T. gondii* bradyzoites and tachyzoites comprise five main members i.e. SAG1 (P30 kDa), SAG2 (P22 kDa), SAG3 (P43 kDa), SAG4 (P23 kDa) and SAG5 (P35 kDa) \[[@B41],[@B42]\]. SAG1 and SAG2A are immunodominant within the superfamily and induce a high antibody response in early infection. The increased mRNA expression level of SRS34A (SAG2A) which has been detected by IgM in this study is in agreement with other studies which reported that tachyzoite surface is dominated by SAG1, SAG2A, SAG3, SRS1, SRS2 and SRS3 and have been shown to be involved in attachment and invasion necessary for early acute *T. gondii* infection \[[@B43]\].

Conclusion
==========

This study identified several *T. gondii* genes with up-regulated expression *in-vivo* as compared to *in-vitro*. Further studies including stage-specific expression and localisation studies on the highly up-regulated genes and the corresponding proteins, in particular the hypothetical proteins, should be performed. This may help to increase our understanding of the disease pathogenesis and asses their usefulness as potential vaccine candidates.
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